Medical devices, healthcare technology and the business of care
PMA approval · P160015

AED Plus and Fully Automatic AED Plus

ZOLL MEDICAL CORPORATION · Decision date May 26, 2017

MEDTECHLEDGER EXPLANATIONP160015

What did the FDA approve?

FDA approved the AED Plus and Fully Automatic AED Plus from ZOLL Medical Corporation on May 26, 2017, under PMA number P160015. The approval statement describes the devices as indicated for suspected cardiac arrest when a victim shows unconsciousness, absence of normal breathing, and absence of a pulse or signs of circulation. The statement specifies that use is intended for personnel trained in basic life support/AED, advanced life support, or a physician-authorized emergency medical response program.

For victims under 8 years of age or weighing less than 55 lbs (25 kg), the statement says the devices should be used with the ZOLL AED Plus and Fully Automatic AED Plus Pediatric Electrodes. It also states that therapy should not be delayed to determine exact age or weight. The source record does not include a supplement type or reason, and it does not describe clinical testing, comparative performance, or safety outcomes beyond the approved indication and use conditions.

FDA approval order statement

Approval for the AED Plus and Fully Automatic AED Plus. These devices are indicated for use when a suspected cardiac arrest victim has an apparent lack of circulation as indicated by:1) Unconsciousness;2) Absence of normal breathing; and3) Absence of a pulse or signs of circulationThese devices are intended for use by personnel who have been trained in their operation. Users should have received training in basic life support/AED, advanced life support or a physician-authorized emergency medical response training program.When a victim is less than 8 years of age, or weighs less than 55 lbs. (25kg), the ZOLL AED Plus and Fully Automatic AED Plus should be used with the ZOLL AED Plus and Fully Automatic AED Plus Pediatric Electrodes. Therapy should not be delayed to determine the patients exact age or weight.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
May 26, 2017

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P160015
Regulatory pathway
Premarket approval application
Product code
MKJ
Decision code
APPR
Decision date
May 26, 2017
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Automated external defibrillators (non-wearable).

Product code
MKJ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P160015 received

    Application receipt date recorded by FDA.

  2. P160015 · FDA decision

    APPR

  3. P160015/S029 · Related supplement

    AED 3 Defibrillator with Uni-Padz

Timeline entries are records held by MedtechLedger for P160015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160015

Product / regulatory recordCompanyPathwayDecision dateSource
ZOLL MEDICAL CORPORATIONPMA supplementOct 16, 2026FDA

Explore the linked device profile

Other records with product code MKJ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

ZOLL MEDICAL CORPORATION

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
269 & 271 Mill Rd., Chelsmford, MA, 01824

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records